BIODEXA PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.3 USD | +79.36% |
|
+72.87% | -51.49% |
| Apr. 26 | Sector Update: Health Care Stocks Edge Higher Late Afternoon | MT |
| Apr. 26 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.58M 5.72M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 21 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 57.92% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +79.36% | ||
| 1 week | +72.87% | ||
| Current month | -19.75% | ||
| 1 month | +51.34% | ||
| 3 months | -31.94% | ||
| 6 months | -66.06% | ||
| Current year | -51.49% |
1 week
0.67
1.74
1 month
0.671.74
Current year
0.672.74
1 year
0.6720.80
3 years
0.675 776.00
5 years
0.6721 760.00
10 years
0.67587 200.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 62 | 19-09-08 |
Dan Palmer
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Tech/Sci/R&D Officer | 44 | 21-07-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Parker
CHM | Chairman | 65 | 22-06-19 |
Sijmen de Vries
BRD | Director/Board Member | 65 | 14-10-28 |
Stephen Stamp
CEO | Chief Executive Officer | 62 | 19-09-08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.3 | +79.36% | 70,819,736 |
| 24-04-25 | 0.7248 | -3.35% | 138,398 |
| 24-04-24 | 0.7499 | -7.20% | 149,305 |
| 24-04-23 | 0.8081 | +5.63% | 77,534 |
| 24-04-22 | 0.765 | +1.73% | 102,167 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Calendar
2024-09-11
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.044
GBP
Average target price
6.337
GBP
Spread / Average Target
+507.17%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -51.49% | 5.7M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BDRX Stock
